RE: Half year report10 Feb 2022 20:25
From last years EOY RNS " Manufacturing scale-up from 1 litre to 600 litres had been completed successfully and with the formal handover of the project from Sederma in Paris to Croda's manufacturing facility at Ditton, near Widnes, the final scale-up to 20,000 litres is now being progressed. This is the capacity required to mass produce the SkinBiotix® product at industrial levels to market to Sederma's portfolio of 12,000+ global cosmetic customers.
Throughout this collaboration, Sederma has identified additional potential scientific and marketing claims for the end ingredient. The eventual claims will be an important component of the launch and long-term commercial success of the ingredient. To this end, Sederma is continuing its lab work to further substantiate these additional potential claims. This work is not impacting the manufacturing scale-up. The Group continues to anticipate 2022 as the period for initial royalty revenues."
This officially tells me that the manufacturing scale-up has not been impacted by substantiating the improvement claims, and we have also been told by Stuart he will RNS once final scale up has been achieved. It also does not mention whether the launch will take place in Q1, Q2, Q3 or Q4, although we have been told that the 600 litre capacity achieved by Sederma from their plant rather than the Widnes final scale-up operation, is repeatable every 18 hrs and is sufficient to meet the demand of the preferred "12" selected beauty clients who will launch in advance of the rest, and hence no surprise that belgrano can find no mention of the skinbiotix ingredient advertising to the balance of the 12000 clients on the Croda website
Sign In
Follow the stocks
